FTC judge says Impax should settle

Impax Laboratories should settle the Federal Trade Commission’s allegations that it entered into a pay-for-delay agreement with Endo Pharmaceuticals, an administrative law judge suggested on Thursday.

Get unlimited access to all Global Competition Review content